Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Dec 06, 2024

AL Amyloidosis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Janssen Pharma, Prothena, Alexion Pharma, Alnylam Pharma, Attralus, Neurimmune AG

Read more

Dec 06, 2024

Acoramidis Sustains Benefits in Patients With ATTR-CM in Open-Label Extension Study

Read more

Nov 26, 2024

BridgeBio Selects PANTHERx® Rare Specialty Pharmacy for Distribution of Attruby™ (acoramidis)

Read more

Nov 25, 2024

Look out, Pfizer: BridgeBio scores 'best-case' FDA nod for Attruby in cardiomyopathy

Read more

Nov 25, 2024

Acoramidis Snags FDA Approval for ATTR Cardiomyopathy

Read more

Nov 23, 2024

BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer

Read more

Nov 22, 2024

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Read more

Nov 22, 2024

Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients

Read more

Nov 18, 2024

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

Read more

Nov 12, 2024

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Read more

Subscribe to